![CG Oncology](https://gocience.com/logos/new/530fc6c7fabfae85484d15df5e82ed8237bc27efba0118360f038f4fcc8a5e63.jpg)
Cg Oncology
Biotechnology, 400 Spectrum CTR Dr Ste 2040, Irvine, California, 92618, United States, 11-50 Employees
Who is CG ONCOLOGY
CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where uro...
Read More
![map](/x-assets/maps1.0-950f22e3512fa69a51fdf6612dcb593a74c2f8790b6e4ec5601cebb82b592ab9.png)
-
Headquarters: 400 Spectrum CTR Dr Ste 2040, Irvine, California, 92618, United States
-
Date Founded: 2010
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO: Jennifer Franco
Industry: Biotechnology
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from CG ONCOLOGY
CG Oncology Org Chart and Mapping
Jennifer Franco
Senior Executive Assistant to Chief Executive Officer & Chief Medical Officer
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CG Oncology
Answer: CG Oncology's headquarters are located at 400 Spectrum CTR Dr Ste 2040, Irvine, California, 92618, United States
Answer: CG Oncology's official website is https://cgoncology.com
Answer: CG Oncology's revenue is $1 Million to $5 Million
Answer: CG Oncology's SIC: 2834
Answer: CG Oncology has 11-50 employees
Answer: CG Oncology is in Biotechnology
Answer: CG Oncology contact info: Phone number: Website: https://cgoncology.com
Answer: CG Oncology is a privately held oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. Our lead candidate, CG0070, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. CG0070 is also in a Phase 2 study in combination with KEYTRUDA (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with CG0070 in combination with OPDIVO (nivolumab).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
CEO at CG Oncology
Jennifer Franco
Senior Executive Assistant to Chief Executive Officer & Chief Medical Officer
Sign in to CIENCE GO Data to uncover contact details
Free credits every month